KTRA Projected Dividend Yield
Kintara Therapeutics Inc ( NASDAQ : KTRA )Kintara Therapeutics is a clinical stage biopharmaceutical company. Co.'s two primary candidates are: VAL-083, a validated, DNA-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer. PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of reactive oxygen that induces local tumor cell death. 20 YEAR PERFORMANCE RESULTS |
KTRA Dividend History Detail KTRA Dividend News KTRA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |